president Donald Trump New measures were announced on Tuesday to reduce the costs of prescribed medicines, which include increasing competition and creating transparency.
Newsweek He spoke to two experts about the possibility of the success of new measures.
Why do it matter
The president signed an executive order on Tuesday telling the Ministry of Health and Humanitarian Services (HHS) to take steps to reduce medicine prices.
This was one of the promises of Trump campaign before the elections last year after efforts to reduce costs during his first term.
It is assumed that “Trump’s order” is improving “the former president Joe BidenIRA, which aims to reduce drug prices for people with medical care and reduce drug spending by the federal government.
Photo verbs by Newsweek/Getti
What do experts say?
Juliet Cubanski, deputy director of the KFF medical policy policy program, a non -profit health policy research organization, praised Trump’s efforts, but he said that his measures do not include anything “will quickly translate into a large -scale drug prices without more concrete legislative or regulatory procedures.”
“In fact, this is to push many methods here. For example, encourage faster work in FDA [Food and Drug Administration] In the state import plans, or the work of the HHS secretary with Congress On the changes in the law to reduce inflation, or renew the regulations that govern the implementation of the drug negotiation program in Medicare, ” Newsweek.
“It is extremely reasonable for the president to express the support of policies aimed at high prices of medicines, because it is a real problem in the pocket book for consumers and the highest minds of people when it comes to the ability to bear the costs of their health care costs,” Kubianski said.
She said: “But whether these administrative and organizational procedures are to what extent will these administrative and organizational procedures be translated into tangible and permanent policies that the low costs of the prescribed drugs for consumers are an open question.”
Meanwhile, Stacie B. Dusetzina, a doctorate, a professor in the Department of Health Policy and Professor of Ingram Research Research at the Faculty of Medicine at Vanderbelt University, has called the Food and Drug Administration (FDA) of the administration.
She told Newsweek.
AP
Thousands of federal employees via HHS earlier this month I started receiving workers’ discharge notifications In what the Trump administration described as a comprehensive reorganization of the Agency responsible for public health, food safety and medical research.
The Food and Drug Administration (FDA) will lose 3,500 jobs, which are the United States Centers to control and prevent diseases (CDCThe National Health Institutes (NIH) will lose 2400, and will lose the Medicare and Medicaid (CMS) 300, according to the HHS figures.
The administration defended the discounts as a necessary efficiency procedure, on the pretext that the health results did not improve in proportion to the agency’s financing levels.
“The president has suggested many political goals that contradict many other measures that the administration has taken in recent weeks,” said Dossetzina, before adding, for example. Looking at the recent definitions and relationshipsI will not hold my breath. “
Newsweek I contacted the Ministry of Health and Humanitarian Services to respond to these comments.
Since Trump became president, the customs tariff was a major part of his political shows, although he temporarily stopped many of those who put in place.
Last year, the United States Imported medicines worth $ 213 billionWith a minimal or non -import tax due to the 1995 World Trade Organization Agreement.
What measures did Trump requested?
- Drug import: Directing the FDA to allow the import of some low -cost prescribed medications from Canada and other countries.
- Fur approvals than OTC: The FDA request to accelerate the approval of safe and effective medicines that do not depict prescription.
- Transparency at high prices: Medicare and Medicaid require the inclusion of drugs that suffer from a significant increase in prices.
- Patients ’discounts: Putting the finishing touches on a base that imposes on the pharmacy allocations to pass the discounts directly to patients in the pharmacy.
- Medicare Part D Cap: Support legislation for costs of the elderly registered at Medicare Part D.
- Price transparency: Click on hospitals and insurance companies to detect prices to increase competition and enable decisions to make the patient.
The administration said that these measures are designed to expand access, reduce costs outside the pocket, and improve prices for prices through the health care system.
